Apotex_ad.qxp 18/9/07 3:48 pm Page 41
Hepatitis B Immune
Globulin Intravenous (Human) ON GUARD
to prevent hepatitis B virus (HBV)
recurrence following liver
transplantation
Prevention of HBV recurrence –
HepaGam B is the first FDA
Efficacy of HepaGam B
approved IV HBIG for the
vs Historic Control
1
*
100
prevention of HBV recurrence
90
following liver transplantation
80
86%
T
in HBsAg-positive liver
70
transplant patients.
2
ost OL
60
Convenient dosing and
50
atients Remaining
administration – total infusion
40
time of less than 20 minutes
30
cent of P
HBsAg-Negative P
when a 35 mL dose is infused
P
er
20
at a rate of 2 mL per minute.
2
*
10 13%
0
*Volume of the dose will vary based on potency.
HepaGam B Historic Control**
Please refer to full prescribing information.
*Based on a single positive HBsAg
Safe and well tolerated
†
–
value >4 weeks post OLT
**Retrospective untreated control
only 2 adverse drug reactions group of historical patients with
data gathered by chart review
of tremor and hypotension were
reported in 2 patients.
2‡
†Please refer to Important Safety Information below.
‡Based on 14 patients in an ongoing, multicenter, superiority study
For more information please contact
Apotex at 1-877-HepaGamB (437-2426)
or visit
www.HepaGamB.com
References: 1) Unpublished data on file; Cangene Corporation, 2007. 2) HepaGam B full prescribing
information; April 2007.
HepaGam B is a registered trademark of Cangene Corporation. © 2007 Apotex Corp. All rights reserved. APOCAN-030-01
IMPORTANT SAFETY INFORMATION: HepaGam B
TM
(Hepatitis B Immune Globulin Intravenous [Human]), is a sterile solution of
gamma globulin (IgG) made from human plasma. Products made from human plasma may carry a risk of transmitting infectious
agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Individuals known to have severe, potentially
life-threatening reactions to human globulin preparations should not receive HepaGam B
TM
or any other immune globulin
(Human). Individuals who are deficient in IgA may have the potential for developing IgA antibodies and have severe, potential-
ly life-threatening allergic reactions. The maltose contained in HepaGam B
TM
can interfere with some types of blood glucose mon-
itoring systems. Only testing systems that are glucose-specific should be used in patients receiving HepaGam B
TM
. This interference
can result in falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administra-
tion, resulting in life-threatening hypoglycemia. The most common expected adverse drug reactions for immune globulins like
HepaGam B
TM
are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia and moderate low back pain.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100